The role of urinary KIM-1, NGAL, CA19-9 and beta 2-microglobulin in the assessment of ureteropelvic junction obstruction in adults
Carregando...
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2017
Título da Revista
ISSN da Revista
Título do Volume
Editora
TAYLOR & FRANCIS LTD
Citação
BIOMARKERS, v.22, n.7, p.682-688, 2017
Resumo
Purpose: The objective of this study is to evaluate the diagnostic properties of urinary biomarkers in adults with ureteropelvic junction obstruction: KIM-1, NGAL, CA19-9, and beta 2-microglobulin. We also assessed urinary biomarker concentrations following pyeloplasty. Material and methods: We prospectively studied adults from December 2013 to February 2015. We included 47 patients with a mean age of 38.6 +/- 12.7 years. Each patient provided four samples of voided urine for biomarker measurement, one at pre-operative consultation and the others at 1, 3, and 6 months of post-operative follow-up. The control group consisted of 40 healthy individuals with no hydronephrosis on ultrasound evaluation. Results: KIM-1 had an area under the curve of 0.79 (95% CI 0.70-0.89), NGAL 0.71 (95% CI 0.61-0.83), CA19-9 0.70 (95% CI 0.60-0.81), and beta 2-microgloblin 0.61 (95% CI 0.50-0.73). KIM-1 was the most sensitive marker with a cut-off of 170.4 pg/mg creatinine (sensitivity 91.4%, specificity 59.1%), whereas CA19-9 was the most specific with a cut-off of 51.3 U/mg creatinine (sensitivity 48.9%, specificity 88.0%). Urinary concentrations of biomarkers decreased after pyeloplasty. Conclusions: The evaluation of urinary biomarkers is useful in adults undergoing pyeloplasty. KIM-1, NGAL, and CA19-9 were elevated and significantly decreased after surgery.
Palavras-chave
Ureteral obstruction, hydronephrosis, kidney injury molecule-1, lipocalins, CA-19-9 antigen, beta 2-microglobulin
Referências
- Aybek H, 2006, INT J UROL, V13, P1380, DOI 10.1111/j.1442-2042.2006.01593.x
- Bartoli F, 2011, J PEDIATR SURG, V46, P530, DOI 10.1016/j.jpedsurg.2010.07.057
- Castagnetti M, 2008, BJU INT, V102, P862, DOI 10.1111/j.1464-410X.2008.07597.x
- Caubet C, 2010, PEDIATR NEPHROL, V25, P27, DOI 10.1007/s00467-009-1251-5
- Chertin B, 2002, BJU INT, V90, P72, DOI 10.1046/j.1464-410X.2002.02829.x
- Chevalier RL, 2004, J UROLOGY, V172, P852, DOI 10.1097/01.ju.0000129542.22043.ef
- Cost NG, 2013, J UROLOGY, V190, P1462, DOI 10.1016/j.juro.2013.05.003
- Decramer S, 2007, WORLD J UROL, V25, P457, DOI 10.1007/s00345-007-0201-8
- El-Sherbiny MT, 2002, J UROLOGY, V168, P1798, DOI 10.1097/01.ju.0000027231.84450.8f
- Endre ZH, 2008, NEPHROLOGY, V13, P91, DOI 10.1111/j.1440-1797.2007.00905.x
- Grandaliano G, 2000, KIDNEY INT, V58, P182, DOI 10.1046/j.1523-1755.2000.00153.x
- Kajbafzadeh AM, 2010, J UROLOGY, V183, P2353, DOI 10.1016/j.juro.2010.02.031
- Kausik Sankar, 2003, Int. braz j urol., V29, P3, DOI 10.1590/S1677-55382003000100002
- Khan F, 2014, NAT REV UROL, V11, P629, DOI 10.1038/nrurol.2014.240
- Lam JS, 2007, J UROLOGY, V177, P1652, DOI 10.1016/j.juro.2007.01.056
- Lam W, 2015, UROLOGY, V85, P246, DOI 10.1016/j.urology.2014.09.033
- Lucarelli G, 2014, BIOMED RES INT, DOI 10.1155/2014/303298
- Madsen MG, 2013, J PEDIATR UROL, V9, P838, DOI 10.1016/j.jpurol.2012.11.011
- Madsen MG, 2012, PEDIATR NEPHROL, V27, P2099, DOI 10.1007/s00467-012-2217-6
- Madsen MG, 2011, J PEDIATR UROL, V7, P105, DOI 10.1016/j.jpurol.2010.12.004
- Mesrobian HGO, 2012, PEDIATR CLIN N AM, V59, P839, DOI 10.1016/j.pcl.2012.05.008
- Papachristou F, 2014, BIOMARKERS, V19, P531, DOI 10.3109/1354750X.2014.943292
- Park JM, 1998, UROL CLIN N AM, V25, P161, DOI 10.1016/S0094-0143(05)70004-5
- Taha MA, 2007, J UROLOGY, V178, P640, DOI 10.1016/j.juro.2007.04.006
- Taha MA, 2007, UROLOGY, V69, P560, DOI 10.1016/j.urology.2006.09.070
- Taha MA, 2007, BJU INT, V99, P899, DOI 10.1111/j.1464-410X.2006.06641.x
- TAPIA J, 1995, J UROLOGY, V154, P218, DOI 10.1016/S0022-5347(01)67280-X
- Wasilewska A, 2011, PEDIATR NEPHROL, V26, P579, DOI 10.1007/s00467-011-1773-5